Surge

Company Overview

Surge is a healthcare technology company focused on personalizing patient care for surgical procedures through advanced immune system analysis and prediction of postoperative complications. Founded in Silicon Valley, Surge aims to revolutionize perioperative care by leveraging immunological fingerprinting technology to provide accurate risk assessments and enable tailored interventions.

The company’s mission is to deliver accurate predictions for complication-free surgeries, ultimately improving patient outcomes and reducing healthcare costs. Surge operates at the intersection of immunology, biomedical informatics, and precision medicine.

Products Overview

Surge’s primary product is PreCyte Surgical, an immunological fingerprinting technology that provides accurate predictions of surgical complications. Key features of PreCyte Surgical include:

1. High-resolution exploration of the human immune system
2. Identification of actionable predictive information
3. Optimization of preventive strategies
4. Aid in surgical decision-making
5. Personalization of perioperative care pathways

The PreCyte technology allows for:

• Preoperative risk assessment and monitoring of intervention effectiveness
• Intraoperative decision support for surgical approaches
• Postoperative care optimization, including length of stay and rehabilitation planning

Surge is also developing products for predicting surgical site infections and cognitive decline, which are currently in various stages of development from R&D to clinical trials.

Founding Team

Surge was founded by two key individuals:

1. Brice Gaudilliere - Co-founder and Advisory Board Member
   • MD, PhD from Harvard University
   • Associate Professor of Anesthesiology, Perioperative & Pain Medicine at Stanford University
   • Expert in human immunology and single-cell omics technologies
2. Julien Hedou - Co-founder and Chief Executive Officer
   • MS in Engineering from Ecole Polytechnique
   • MS in Biomedical Informatics from Stanford University
   • Expert in biomedical informatics and machine learning

The company is led by a team of six talented individuals from prestigious institutions including Stanford, Harvard, Sorbonne, and Ecole Polytechnique.

Problem and Market Fit

Surge addresses a significant problem in healthcare: the high rate of postoperative complications and their associated costs. With 63 million elective surgeries performed annually in the US and a 30% complication rate for major surgeries, the impact on patient morbidity and healthcare systems is substantial. These complications lead to extended hospital stays, readmissions, patient suffering, disability, and even death.

By providing accurate predictions of surgical complications, Surge aims to enable healthcare providers to:

1. Personalize patient care
2. Optimize surgical decision-making
3. Implement targeted preventive measures
4. Reduce complication rates
5. Decrease healthcare costs

The company’s technology has the potential to significantly impact the perioperative care market by offering a more precise and personalized approach to surgical risk assessment and management.

Business Model

While not explicitly stated, Surge’s business model likely involves:

1. Selling or licensing the PreCyte Surgical technology to healthcare providers and hospitals
2. Offering testing services for preoperative risk assessment
3. Partnering with pharmaceutical and medical device companies for co-development opportunities
4. Potential subscription models for ongoing risk assessment and monitoring services

The company emphasizes opportunities for co-development, suggesting that they are open to partnerships with other companies and clinicians to develop and monitor interventions using their PreCyte technology.

Funding and Runway

On March 22, 2024, Surge announced the closing of a €7.5 million fundraising round. This funding is intended to support the company’s efforts to decrypt the immune system and transform precision medicine. No further details about previous funding rounds or current runway were provided in the given information.

Competitive Landscape

While specific competitors are not mentioned, the company states that PreCyte Surgical offers “significantly better predictive performance than competitor products and scales” for identifying patients at risk for postoperative complications. This suggests that there are other companies or products in the market attempting to address surgical risk prediction, but Surge claims to have superior technology.

Customers

Surge’s primary customers are likely to be:

1. Hospitals and healthcare systems
2. Surgical departments and individual surgeons
3. Anesthesiology departments
4. Pharmaceutical and medical device companies (for co-development opportunities)

The company mentions partnerships with several institutions, including:

• Hôpital Foch
• Stanford University
• BPI France
• 50 Partners

These partnerships may indicate early adopters or research collaborators for Surge’s technology.

Relevant News

1. March 22, 2024: Surge announced the closing of a €7.5 million fundraising round to support their efforts in decrypting the immune system and transforming precision medicine.

2. September 25, 2023: Surge and Arkhn won the AI For Health Challenge of the Île-de-France Region with the PRISMA project, an innovative approach to anticipate post-operative risks in collaboration with Hôpital Foch.

3. June 2, 2023: Surge was voted Start-up of the Year at the French-American Business Awards (FABA 2023), winning both the Jury Prize and the People’s Choice Prize.

4. April 26, 2023: Surge celebrated having five abstracts accepted for presentation at the IARS/AUA (International Anesthesia Research Society/Association of University Anesthesiologists) conference and received a prestigious award for their research team.

These news items demonstrate Surge’s growing recognition in the field and their active engagement in research and development activities.